Sanofi - American Depositary Shares (SNY)

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi (“Sanofi” or “the Company”) (NASDAQ: SNY) for violations of the securities laws.

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

BALA CYNWYD, Pa., June 13, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

BALA CYNWYD, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

BALA CYNWYD, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit

A wave of high-impact announcements is fueling explosive momentum across tech and healthcare stocks. From AI infrastructure to biotech M&A and consumer health expansion, investors are turning to breakout companies under $10 poised for rapid upside.

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET